ALPMY News and Press, Astellas Pharma Inc. ADR

2024-06-01 17:52:36 ET More on Corbus Pharmaceuticals Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets Seeking Alpha’s Quant Rating on Corbus Pharmaceutical...

2024-05-31 13:04:02 ET More on Astellas Pharma Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript Astellas Pharma partners with YASKAWA for innovative cell therapy Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guida...

U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction canc...

2024-05-21 06:38:46 ET More on Astellas Pharma Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Seeking Alpha’s Quant Rating on Astel...

Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies PR Newswire - Focuses on digitizing cell manufacturing processes through robotics technology TOKYO ,...

2024-05-13 13:24:17 ET More on Corbus Pharmaceuticals Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial i...

Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting PR Newswire 16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO , May 13, 2024 /PRNe...

Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor PR Newswire - 154,000 square-foot lab and office facility creates a central location for Astellas' West Coast cell and gene therapy research and bu...

2024-05-02 15:32:05 ET Summary CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024. Pending positive data, plus at the discretion of partn...

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...